MX2022011464A - Tratamiento con epinefrina intranasal en polvo. - Google Patents

Tratamiento con epinefrina intranasal en polvo.

Info

Publication number
MX2022011464A
MX2022011464A MX2022011464A MX2022011464A MX2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A
Authority
MX
Mexico
Prior art keywords
powdered
treatment
intranasal epinephrine
dry powder
solid particles
Prior art date
Application number
MX2022011464A
Other languages
English (en)
Inventor
Galia Temtsin-Krayz
Pavel Kazhdan
Original Assignee
Nasus Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasus Pharma Ltd filed Critical Nasus Pharma Ltd
Publication of MX2022011464A publication Critical patent/MX2022011464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición farmacéutica en forma de polvo seco para administración intranasal, que comprende un agonista del receptor adrenérgico antianafiláctico en forma de polvo seco para administración intranasal, la composición comprende partículas sólidas del agente activo en combinación con al menos un aditivo funcional, y partículas sólidas de un portador inerte.
MX2022011464A 2020-03-16 2021-03-16 Tratamiento con epinefrina intranasal en polvo. MX2022011464A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
PCT/IL2021/050288 WO2021186437A1 (en) 2020-03-16 2021-03-16 Treatment with powdered intranasal epinephrine

Publications (1)

Publication Number Publication Date
MX2022011464A true MX2022011464A (es) 2022-11-14

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011464A MX2022011464A (es) 2020-03-16 2021-03-16 Tratamiento con epinefrina intranasal en polvo.

Country Status (13)

Country Link
US (2) US11400045B2 (es)
EP (1) EP4121005A1 (es)
JP (1) JP2023517532A (es)
KR (1) KR20220154709A (es)
CN (1) CN115279340A (es)
AR (1) AR121593A1 (es)
AU (1) AU2021239084A1 (es)
BR (1) BR112022018440A2 (es)
CA (1) CA3175130A1 (es)
IL (1) IL296268A (es)
MX (1) MX2022011464A (es)
TW (1) TW202200119A (es)
WO (1) WO2021186437A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3962455T (lt) 2020-05-18 2022-10-25 Orexo Ab Nauja farmacinė kompozicija, skirta vaistų tiekimui
MX2024006188A (es) 2021-11-25 2024-06-11 Orexo Ab Nueva composicion farmaceutica que comprende adrenalina.
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
WO2024031148A1 (en) * 2022-08-11 2024-02-15 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5415769B2 (ja) * 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2015034822A1 (en) 2013-09-03 2015-03-12 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
WO2016100949A2 (en) * 2014-12-18 2016-06-23 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
CA3071552A1 (en) 2017-08-20 2019-02-28 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
IL276485B1 (en) * 2018-02-06 2024-08-01 Aegis Therapeutics Llc Intranasal epinephrine formulations and methods for treating the disease

Also Published As

Publication number Publication date
WO2021186437A1 (en) 2021-09-23
EP4121005A1 (en) 2023-01-25
IL296268A (en) 2022-11-01
US20210283050A1 (en) 2021-09-16
CA3175130A1 (en) 2021-09-23
BR112022018440A2 (pt) 2022-11-01
TW202200119A (zh) 2022-01-01
KR20220154709A (ko) 2022-11-22
AR121593A1 (es) 2022-06-22
CN115279340A (zh) 2022-11-01
AU2021239084A1 (en) 2022-10-13
US20230105615A1 (en) 2023-04-06
JP2023517532A (ja) 2023-04-26
US11400045B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2022011464A (es) Tratamiento con epinefrina intranasal en polvo.
TWD193611S (zh) Electrode plate peripheral ring for plasma processing equipment
MX2021013758A (es) Sustrato generador de aerosol novedoso.
SG144820A1 (en) Highly conductive composition for wafer coating
NZ600814A (en) Stents having bioabsorbable layers
WO2006103407A3 (en) New pharmaceutical compositions useful in the treatment of migraine
PH12017501351A1 (en) Encapsulation of high potency active agents
MX2022004521A (es) Sustrato generador de aerosol novedoso que comprende especies de illicium.
MX2022001974A (es) Composiciones y particulas para la administracion de carga util.
MX2007009908A (es) Metodos para tratar linfomas utilizando una combinacion de un agente quimioterapeutico e il-2 y opcionalmente un anticuerpo anti-cd20.
SE0400282D0 (sv) Machine for volumetric filing of powders
MX2009008487A (es) Picoplatino encapsulado.
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
TNSN05048A1 (en) Inhalation compositions with high drug ratios
TW200616611A (en) Stable particle formulations of erythropoietin receptor agonists
MX2021009844A (es) Conservacion de particulas de ingredientes farmaceuticos activos revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspension acuosa.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2021014993A (es) Bolsas que comprenden agentes activos para el cuidado bucal.
GEP20237580B (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
FI129157B (fi) Koostumus käytettäväksi vakavien päänsärkyjen esiintymistiheyden pienentämiseksi tai niiden vähentämiseksi
MX2018009621A (es) Combinaciones de dihidrocloruro de histamina y uso de estas.
AR058107A1 (es) Azodicarbonamida micronizada, su preparacion y su utilizacion
PH12020551798A1 (en) Improved pharmaceutical formulations
MX2021005734A (es) Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b.
WO2019045805A3 (en) PROCESS FOR METALLIZING ELECTROCHEMICALLY ACTIVE POWDERS